Drug intelligence / Profile preview

FX1-5303

Development stage: Unknown
Lead developer: Schrödinger
Modality: Small Molecules

Overview

FX1-5303 is a **highly potent and specific inhibitor** of ubiquitin-specific protease 7 (**USP7**), a member of the deubiquitinase (DUB) enzyme family. It demonstrates a biochemical IC50 of 0.29 nM, indicating strong activity against its target. USP7 is a key regulator of protein degradation pathways relevant to cancer and other cellular processes, and its inhibition is an active area of research in oncology and immunology[1].

Brand names: FX1-5303FX-1-5303FX 1-5303
Other names: FX1-5303FX-1-5303FX 1-5303

Targets

USP7

Beyond the preview

Go deeper on FX1-5303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FX1-5303.

Explore the full profile